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Abstract 
	 	 Histone methylation is implicated in various biological and pathological processes 
including cancer development. In this study, we discovered that ectopic expression of 
KDM5B, a histone H3 lysine 4 (H3K4) demethylase, promoted epithelial-mesenchymal 
transition (EMT) of cancer cells. KDM5B increased the expression of transcription factors, 
ZEB1 and ZEB2, followed by down-regulation of E-cadherin and up-regulation of 
mesenchymal marker genes. The expression of the microRNA-200 (miR-200) family, 
which specifically targets ZEB1 and ZEB2, was reduced in the cells with KDM5B 
overexpression. We found that KDM5B repressed the expression of the miR-200 family by 
changing histone H3 methylation status of their regulatory regions. The introduction of 
miR-200 precursor in the cells inhibited EMT induction by KDM5B, suggesting that 
miR-200 family was a critical downstream mediator of KDM5B-promoted EMT. 
Furthermore, knockdown of KDM5B was shown to affect the expression of EMT-related 
genes, indicating the involvement of endogenous KDM5B. Our study demonstrated a novel 
role of KDM5B histone lysine demethylase in EMT, which may contribute to malignant 
progression of cancer.   
  
-	 4	 -	 
Introduction 
    Histone modifications such as acetylation, phosphorylation and methylation can function 
individually or in combination to elicit specific effects on chromatin structure and gene 
expression.1 Histone lysine (K) methylation, in particular, has emerged as an important 
modification due to its central role in transcriptional regulation. 2,	 3	 Histone lysine 
methylation is associated with activated or repressed transcription of individual genes 
depending on the methylated residue and the degree of methylation, since lysine residues 
can be mono-, di- or tri-methylated (me1, me2 or me3). 4,	 5 Moreover, a given methylated 
mark is often linked to a specific position of the gene, either around the transcription 
initiation site or in the coding region, regulating transcriptional initiation or elongation. In 
general, methylation of lysine-4 of histone H3 (H3K4) around TSS and methylation of 
H3K36 and H3K79 on the coding region are associated with active transcription. 
Methylation of H3K9 and H3K27 on promoters correlates with transcriptional repression.6,7 
The discovery of a large number of site-specific histone methyltransferases and 
demethylases reveals the dynamic regulation of histone methylation.4,	 5 Reversible histone 
lysine methylation is implicated in diverse biological processes including cellular 
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proliferation, differentiation, DNA repair and recombination. The importance of the tight 
regulation of histone methylation is demonstrated by emerging links of histone methylation 
to human disease such as cancer.4 
     Identification of genes involved in cancer gives us crucial information about the 
molecular mechanism of cancer development. Genetic screens for mutations contributing to 
tumor formation in model organisms facilitate the efficient identification of cancer genes in 
an in vivo setting. Retroviral insertional mutagenesis in mice is one of the potent cancer 
gene discovery tools.	 8 Previously we have accomplished high-throughput cloning of 
retroviral integration sites from the tumors of murine leukemia virus (MuLV)-infected 
mice. This screen led to the identification of hundreds of candidate cancer genes including 
many genes encoding histone lysine methyltransferases and demethylases.9,	 10 These results 
provided us with an opportunity to explore the functions of these enzymes in the course of 
cancer development. Previously, we reported that JMJD2C, a histone H3K9 demethylase, 
increased the expression of MDM2 oncogene, resulting in the reduction of p53 tumor 
suppressor in the cells.11 We also showed that UTX H3K27 demethylase enhanced the 
expression of RB1 and RBL2 genes that play important roles in cell proliferation.12 In 
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addition, we demonstrated that KDM5B/PLU1 H3K4 demethylase repressed the expression 
of KAT5/TIP60 and CD82/KAI1 genes, thereby increasing the invasive activity of the 
cancer cells.13 Thus our studies revealed that histone methyl-modifying enzymes were 
involved not only in tumor initiation but also in tumor progression such as invasion and 
metastasis. 
     The increased motility and invasiveness of malignant tumor cells are often associated 
with epithelial-mesenchymal transition (EMT) of the cells.14,	 15 Loss of 
E-cadherin-mediated cell interaction is the most important step and a well-known marker 
for EMT. The up-regulation of mesenchymal markers such as Fibronectin and N-cadherin 
also characterizes EMT process. Many studies on the molecular mechanisms for E-cadherin 
repression have revealed that several transcription factors including SNAI1, SNAI2, ZEB1, 
ZEB2 and TWIST, are involved in the complex network that regulate EMT.16-18 EMT is a 
dynamic and reversible process that primarily occurs at the invasive front of the tumor. 
When cancer cells distribute to distant sites of the body, they can revert to an epithelial state 
via mesenchymal-epithelial transition. The plasticity of EMT suggests that epigenetic 
regulation such as DNA methylation and histone modification is implicated in the EMT 
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process.19,	 20 Recent reports indicated the connection between EMT and histone 
methylation. SNAI1 was shown to interact with LSD1 H3K4 demethylase or G9A H3K9 
methyltransferase and recruited them to CDH1/E-cadherin promoter for transcriptional 
repression during EMT.21,	 22 However, the exploration for the role of histone 
methyltransferase or demethylase in EMT has just begun. 
   Histone H3K4 demethylase KDM5B/PLU1/JARID1B has been reported to play 
important roles in cancer development, since up-regulation of KDM5B was observed in 
many types of malignant tumors.23-26 Previously we reported that KDM5B enhanced the 
invasive potential of cancer cells, clarifying its function in malignant tumor progression.13 
However, the involvement of KDM5B in other processes of cancer progression such as 
EMT remained unknown. 
     In this paper we demonstrated that overexpression of KDM5B promoted the EMT 
process of cancer cells. KDM5B specifically increased the expression of ZEB1 and ZEB2 
transcription factors, the critical regulators of EMT induction. Mechanistic investigations 
indicated that KDM5B regulated the expression of microRNA-200 family targeting ZEB1 
and ZEB2 transcripts through the changes of histone H3 methylation on their regulatory 
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regions.  
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Results 
Ectopic expression of KDM5B induced morphological changes of the cells 
       Previously, we demonstrated that KDM5B/PLU1 histone lysine demethylase played an 
important role in the cell invasion process of cancer progression.13 To investigate the 
involvement of KDM5B in other processes of malignant progression, we examined whether 
ectopic expression of KDM5B would affect epithelial-mesenchymal transition (EMT) of 
cancer cells. We used a lung cancer cell line, A549, because it shows clear morphological 
changes during EMT caused by the treatment of Transforming Growth Factor-beta 
(TGF-β).29 A549 cells were infected with the retroviruses expressing either without insert 
or with FLAG-tagged wild-type KDM5B or catalytically inactive KDM5B mutant H499Y,	 
13,	 25 and the infected cells were selected in the medium containing 800µg/ml of G418. The 
cell lysates of the infected cells were prepared and subjected to Western blot analysis with 
anti-FLAG antibody (Fig. S1A). We confirmed that exogenously introduced wild-type and 
mutant KDM5B proteins were produced at a similar level in A549 cells (Fig. S1A).  
      As a positive control for EMT induction, we used A549 cells treated with TGF-β for 48 
hours. After TGF-β treatment, the cells were dispersed, elongated and assumed a 
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fibroblast-like appearance (Fig. 1A, Control plus TGF-β). Similar morphological changes 
of A549 cells were observed with the expression of wild-type KDM5B but not of inactive 
KDM5B mutant (Fig. 1A, KDM5B WT and Mut), suggesting that overexpression of 
KDM5B might induce EMT. To confirm this, we performed immunofluorescence assay for 
A549 cells using an antibody against E-cadherin, an epithelial cell marker. Untreated A549 
cells showed heterogeneous E-cadherin staining (Fig. 1B, Control), and this staining was 
almost lost in TGF-β-treated cells (Fig. 1B, Control plus TGF-β) as described in the 
previous reports.29 We discovered that E-cadherin staining significantly reduced in the cells 
with the expression of wild-type KDM5B (Fig. 1B, KDM5B WT). No significant change 
was observed after infection with the virus expressing the inactive mutant (Fig. 1B, 
KDM5B Mut). These results indicated that the epithelial property of the cells might be lost 
by the expression of wild-type KDM5B. We further examined the status of actin in the cells 
by TRITC-conjugated phalloidin staining, since actin reorganization occurs during the 
EMT process.17 In contrast to untreated cells (Fig. 1C, Control), treatment of TGF- β 
dramatically induced actin fiber formation typical of EMT (Fig. 1C, Control plus TGF-β). 
Phalloidin staining revealed a similar actin fiber formation in the cells with wild-type 
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KDM5B, but not with the inactive mutant (Fig. 1C, KDM5B WT and Mut).  
   We next examined whether KDM5B overexpression would cause similar effects on other 
EMT models. We used a mouse mammary epithelial cell line, NMuMG, and a human colon 
cancer cell line, HT29, because these cell lines respond to TGF-β for EMT induction. We 
first confirmed the expression level of wild-type and mutant KDM5B proteins in NMuMG 
cells (Fig. S1B) and HT29 cells (Fig. S1C). The expression of wild-type KDM5B but not 
its mutant induced similar morphological changes of NMuMG cells (Fig. S2A) and HT29 
cells (Fig. S3A) as TGF-β treatment did. Moreover, the cells with wild-type KDM5B 
showed disappearance of E-cadherin staining and formation of actin stress fiber (Fig. S2B, 
S2C, S3B and S3C). Altogether, these results indicated that ectopic expression of KDM5B 
caused morphological changes and cytoskeletal rearrangement consistent with EMT in 
A549 lung cancer cells, NMuMG mammary epithelial cells and HT29 colon cancer cells, 
which was dependent on its demethylase activity.  
 
KDM5B affected the expression of EMT related genes 
     Besides the reduction of E-cadherin, EMT is characterized by up-regulation of 
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mesenchymal marker genes.14, 15, 17 Therefore we analyzed the expression of two 
representative mesenchymal marker genes, FN1/Fibronectin and CDH2/N-cadherin, as 
well as an epithelial marker, CDH1/E-cadherin, in the cells with KDM5B expression. 
Quantitative RT-PCR analysis revealed that TGF-β treatment decreased the expression of 
CDH1 mRNA in A549 cells (Fig. 2A) as previously reported.29 Expression of wild-type 
KDM5B similarly reduced the CDH1 expression, but its mutant had no effect (Fig. 2A). On 
the other hand, for FN1 or CDH2 whose expression was elevated by TGF-β, wild-type 
KDM5B increased their expression significantly, but the mutant did not change the 
expression (Fig. 2B and 2C). These results again indicated that the effect was dependent on 
the demethylase activity of KDM5B. Judging from the changes in the epithelial and 
mesenchymal marker gene expression, we could conclude that overexpression of wild-type 
KDM5B induced EMT of A549 cells. 
     During the EMT process, it has been reported that the expression of E-cadherin is 
regulated by multiple transcriptional repressors.16, 17 Thus we investigated whether 
overexpression of KDM5B affected the expression of transcription factors such as SNAI1, 
SNAI2, ZEB1 and ZEB2. Quantitative RT-PCR analysis showed that TGF-β treatment 
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up-regulated the expression of all transcription factors we examined in A549 cells (Fig. 2D, 
2E, 2F and 2G). Expression of wild-type KDM5B did not affect the expression of SNAI1 
and SNAI2 significantly (Fig. 2D and 2E), but resulted in the increased expression of ZEB1 
and ZEB2 in A549 cells (Fig. 2F and 2G). We also confirmed the changes of protein 
expression for some of the EMT-related gene products in A549 cells. Western blot showed 
that the expression of wild-type KDM5B resulted in the reduction of E-cadherin protein 
and the increase of ZEB1 and ZEB2 proteins as TGF-β treatment did (Fig. 2H).  
   Quantitative PCR and Western blot revealed that KDM5B overexpression induced 
essentially the same changes for the EMT-related gene expression in NMuMG mammary 
epithelial cells (Fig. S4A to S4H), although endogenous ZEB2 protein was not detected 
because of its extremely low expression in NMuMG cells.  Moreover, in HT29 colon 
cancer cells, KDM5B resulted in the similar changes for the EMT-related gene expression 
(Fig. S5A to S5E), although endogenous expression of CDH2/N-cadherin, SNAI2 and ZEB2 
was extremely low or not detected in HT29 cells. These results together suggested that 
KDM5B histone lysine demethylase might be specifically involved in the regulation of 
ZEB family expression and then control the transcriptional network leading to EMT. 
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KDM5B did not seem to be directly involved in the expression of CDH1/E-cadherin, 
ZEB1 or ZEB2 
   Since KDM5B is an enzyme that possesses a demethylase activity of histone H3 to 
regulate gene expression,23-25 we examined the recruitment of KDM5B and the methylation 
status of histone H3 on the regulatory regions of CDH1/E-cadherin, ZEB1 or ZEB2 gene. 
Chromatin immunoprecipitation (ChIP) assay was performed using antibodies that 
specifically recognize methylated K residues of histone H328 or FLAG epitopes. A549 cells 
were infected with the control retrovirus or the retrovirus expressing FLAG-tagged 
wild-type KDM5B, and the cell lysates were prepared. Following immunoprecipitation, 
total ten different primer sets positioned upstream or around the transcription initiation sites 
of CDH1, ZEB1 and ZEB2 gene were used in quantitative PCR analysis (Fig. 3A, 3C, 3E, 
S6A, S7A and S8A). We analyzed the transcriptionally active tri-methylated H3K4 
(H3K4me3) status and the repressive H3K27me3 status on the regulatory region of each 
gene. As a representative result for each gene locus, the data from one primer set (region a) 
was presented (Fig. 3B, 3D and 3F). The data obtained from all other primer sets were 
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shown in Fig. S6B, S7B and S8B. In the case of CDH1 gene, H3K4me3 was significantly 
decreased and H3K27me3 was slightly increased in the regions around the transcription 
initiation site with the expression of wild-type KDM5B (Fig. 3B and S6B). Since CDH1 
expression was down-regulated by KDM5B, this observation was consistent with the 
previous report showing low level of H3K4me3 and high level of H3K27me3 on the 
regulatory regions were linked to transcriptionally repressed status.6 However, the 
recruitment of KDM5B was not detected on the all regions of CDH1 gene that we have 
tested (Fig. 3B and S6B). These results suggested that KDM5B did not seem to be directly 
involved in the transcriptional regulation of CDH1. On the other hand, we did not detect 
any significant changes of H3K4me3, H3K27me3 and the recruitment of KDM5B on the 
all regions of ZEB1 and ZEB2 genes that we have examined (Fig. 3D, 3F, S7B and S8B). 
These results might also exclude the direct involvement of KDM5B in the transcriptional 
regulation of ZEB1 and ZEB2 genes in the cells with KDM5B overexpression.  
 
KDM5B regulated the expression of the microRNA-200 family gene through the 
conversion of histone H3 methylation 
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     The finding that KDM5B increased ZEB1 and ZEB2 expression specifically and 
indirectly in the EMT process led us to investigate the possibility that the effect could be 
due to the regulation of the miR-200 family of microRNAs. The miR-200 family has been 
established as a key regulator of epithelial phenotype, and is known to be deeply involved 
in the EMT process.30, 31 The miR-200 family was found to directly target and inhibit ZEB1 
and ZEB2 specifically. Genetically, the miR-200 family is grouped in two polycistronic 
units: miR-200b/200a/429 and miR-200c/141, clustered in chromosome 1 and 12, 
respectively (see Fig. 4C and 4E). Therefore we examined whether KDM5B 
overexpression would affect the expression of two representative microRNAs, miR-200a 
and miR-200c. Consistent with the previous reports,30 quantitative RT-PCR revealed that 
TGF-β treatment resulted in a decreased expression of miR-200a and miR-200c in A549 
cells (Fig. 4A and 4B). We could also detect a decrease in the expression of miR-200a and 
miR-200c with the expression of wild-type KDM5B but not with its mutant (Fig. 4A and 
4B). The expression of miR-302a that belongs to an unrelated miR-302 family was not 
significantly affected by KDM5B expression (data not shown), suggesting the specific 
effect of KDM5B on the miR-200 family.  We also found the similar down-regulation of 
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miR-200a and miR-200c induced by wild-type KDM5B in NMuMG cells and HT29 cells 
(Fig. S9). These results strongly suggested that KDM5B was implicated in the regulation of 
the miR-200 family expression and involved in the EMT process through this regulation. 
   Next we examined the methylation status of histone H3 on the regulatory regions of the 
miR-200 family genes by ChIP analysis. As shown in Fig. 4C and 4E, the transcription 
initiation sites of miR-200b/200a/429 and miR-200c/141 precursor RNAs were reported 
previously.32, 33 Following immunoprecipitation, the two primer sets positioned around the 
transcription initiation sites of the microRNA clusters were used in quantitative PCR 
analysis (Fig. 4C and 4E). On the regulatory regions of both miR-200b/200a/429 and 
miR-200c/141 genes, the level of H3K4me3 was dramatically decreased by the expression 
of KDM5B (Fig. 4D and 4F). Moreover, ChIP assay using anti-FLAG antibody clearly 
demonstrated the increased occupancies of FLAG-tagged wild-type KDM5B on the 
regulatory regions (Fig. 4D and 4F). The level of repressive H3K27me3 mark was 
significantly increased by KDM5B expression (Figure 4D and 4F), which was correlated 
with the transcriptional repression by KDM5B. These results suggested that KDM5B which 
was recruited on the regulatory regions of miR-200b/200a/429 and miR-200c/141 genes 
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converted the chromatin structure to a more transcriptionally repressed status by 
demethylating H3K4. As a control experiment, we performed ChIP assay on the regulatory 
regions of BRCA1 and HOXA5 genes that were reported to be the target genes regulated by 
KDM5B25	 and also unrelated GAPDH gene (Fig. S10). In the case of BRCA1 and HOXA5 
genes, the decrease of H3K4me3 and the increase of H3K27me3 were detected 
simultaneously with the recruitment of KDM5B on the regulatory regions (Fig. S10B and 
S10D). On the other hand, there were no significant changes in H3K4 and H3K27 
methylation and KDM5B occupancies on the regulatory regions of GAPDH gene by 
KDM5B (Fig. S10F). These results indicated that KDM5B-induced changes of histone H3 
methylation were specific to the target genes regulated by KDM5B including 
miR-200b/200a/429 and miR-200c/141 genes, which was closely correlated with the 
specificity of transcriptional regulation by KDM5B. 
 
The regulation of miR-200 family expression was important in KDM5B-induced EMT 
   In order to clarify the role of the miR-200 family down-regulated by KDM5B in EMT, 
we transfected the precursor of miR-200a or miR-200c into KDM5B-expressing A549 cells 
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to see the rescue effects in the EMT process. Fig. 5A showed that the expression of 
wild-type KDM5B decreased CDH1/E-cadherin expression but simultaneous introduction 
of miR-200a or miR-200c precursor recovered CDH1 expression. Transfection of 
miR-200a or miR-200c was also shown to inhibit the enhanced expression of mesenchymal 
marker CDH2/N-cadherin by KDM5B (Fig. 5B). These results suggested that 
over-expression of miR-200a or miR-200c inhibited EMT induction by KDM5B 
expression. Moreover, the expression of miR-200a or miR-200c counteracted the enhanced 
expression of ZEB1 and ZEB2 induced by KDM5B (Fig. 5C and 5D), but had no effect on 
the expression of SNAI1 and SNAI2 (data not shown). We found that the introduction of 
miR-200a or miR-200c precursor resulted in the loss of mesenchymal cell appearance of 
the KDM5B-expressing cells by the staining of E-cadherin and actin (Fig. S11A and 
S11B). We also confirmed that the expression of miR-200a or miR-200c did not affect the 
expression level of KDM5B proteins (Fig. S12). These results clearly indicated the 
inhibitory function of these microRNAs in EMT process induced by KDM5B. Taken 
together, we could conclude that the reduced expression of miR-200a and miR-200c was 
primarily responsible for the EMT induction by KDM5B overexpression. 
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Knockdown of KDM5B indicated the involvement of endogenous KDM5B in the 
transcriptional regulation of EMT-related genes  
      To extend our understanding for the regulation of EMT by KDM5B, we examined the 
effects of KDM5B knockdown in the cells. We used the retroviruses expressing small 
hairpin RNA (shRNA) for efficient and stable knockdown of KDM5B as described 
previously.13 A549 cells were infected with the control retrovirus or the retrovirus 
expressing KDM5B shRNA, and we examined the expression of CDH1/E-cadherin, 
FN1/Fibronectin and CDH2/N-cadherin in the cells with KDM5B knockdown by 
quantitative RT-PCR. Knockdown of KDM5B increased the CDH1 expression, but 
decreased the expression of FN1 and CDH2 (Fig. 6A, 6B and 6C). These results indicated 
that KDM5B knockdown resulted in the opposite effects compared to KDM5B 
overexpression. By immunofluorescence, KDM5B knockdown induced stronger staining of 
E-cadherin on the cell membrane compared to control cells (Fig. S13A, KDM5B sh versus 
Control), but had no effect on actin organization (Fig. S13B). Next we examined the 
expression of EMT-related transcription factors by quantitative RT-PCR and found that 
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KDM5B knockdown decreased the expression of ZEB1 and ZEB2 (Fig. 6D and 6E). We 
also confirmed the corresponding changes of protein expression for E-cadherin, ZEB1 and 
ZEB2 in A549 cells by KDM5B knockdown (Fig. 6F). Furthermore, we found that the 
expression of miR-200a and miR-200c was elevated in the KDM5B knockdown cells (Fig. 
6G and 6H). From the ChIP experiments, we could detect the increase of H3K4me3 and the 
decrease of H3K27me3 on the regulatory regions of miR-200b/200a/429 and miR-200c/141 
genes induced by KDM5B knockdown (Fig. 6I and 6J). These results indicated that 
endogenous KDM5B was involved in the transcriptional regulation of EMT-related genes 
in A549 cells. Next we examined whether KDM5B knockdown could be refractory to 
TGF-β-induced EMT process. KDM5B knockdown did not affect the loss of E-cadherin 
staining and actin fiber formation induced by TGF-β (Fig. S13A and S13B, KDM5B sh 
plus TGF-β versus Control plus TGF-β) . Based on the quantitative PCR analyses for 
EMT-related gene expression, KDM5B knockdown did not counteract with TGF-β-induced 
changes of gene expression, either (Fig. S14A to S14E). Finally, it was shown that the level 
of endogenous KDM5B was slightly but significantly increased after TGF-β  treatment in 
A549 cells (Fig. S15).  Taken together, these results suggested that endogenous KDM5B 
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played an important role in the transcriptional regulation of EMT-related genes possibly 
through the regulation of the miR-200 family expression, although TGF-β treatment could 
overcome the depletion of KDM5B for the induction of EMT of the cells.  
 
Significant association between KDM5B and ZEB family expression in human lung 
cancer tissues 
    The finding that KDM5B resulted in the increased expression of ZEB family 
transcription factors led us to examine the correlation between KDM5B and ZEB family 
expression in human cancer specimens. Quantitative RT-PCR analysis was performed to 
detect the expression of KDM5B, ZEB1 and ZEB2 in human lung cancer tissues (N=24). To 
determine the possible relationship of KDM5B and ZEB family, we compared the gene 
expression results using Pearson correlation coefficient. As shown in Fig. 7, each dot 
represented the values of two genes (i.e., x-and y-axis) and the correlation coefficient 
reflected an association between the two genes. We detected a significant association of 
KDM5B and ZEB1 expression (Fig. 7A) or KDM5B and ZEB2 expression (Fig. 7B). The 
associations were positive with r=0.442 (P < 0.05) and with r=0.601 (P < 0.005), 
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respectively. These results suggested that KDM5B might regulate the expression of ZEB 
family, one of the critical EMT inducers, during the development of human lung cancer.  
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DISCUSSION 
     In the current study, we found that ectopic expression of KDM5B H3K4 demethylase 
enhanced the expression of ZEB1 and ZEB2 and resulted in decreased CDH1/E-cadherin 
expression, thereby promoting EMT. This effect of KDM5B was commonly observed in 
several EMT model systems including A549 human lung cancer cells, HT29 colon cancer 
cells and NMuMG mouse mammary epithelial cells. KDM5B was shown to regulate the 
expression of the microRNA-200 family, which specifically inhibits ZEB1 and ZEB2, 
through the conversion of histone H3 methylation on their regulatory regions. We also 
showed that knockdown of KDM5B affected the expression levels of EMT-related genes, 
suggesting the involvement of endogenous KDM5B. Moreover, we detected a positive 
association between KDM5B and ZEB family expression in human lung cancer tissues. Our 
study uncovers a novel role of KDM5B histone lysine demethylase in EMT, and has 
important implication in targeting cancer metastasis. 
     A growing body of evidence indicates that overexpression or mutations of histone 
methyltransferases and demethylases have been linked to the development of many human 
cancers.4 A histone H3K27 methytransferase, EZH2, and H3K4 demethylases, LSD1 and 
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KDM5B have been thought to play important roles not only in tumor initiation but also in 
tumor progression, since overexpression of these genes has been reported in many types of 
malignant tumors.	 24,	 26,	 34-37 Previous papers revealed that up-regulation of EZH2 or LSD1 
enhanced cell migration, cell invasion and EMT to promote malignant progression of 
cancer cells.35,	 36	 During the EMT process, it was shown that EZH2 repressed E-cadherin 
gene expression35	 and that LSD1 interacted with SNAI1 to repress E-cadherin and other 
epithelial genes.21 Although we previously reported that overexpression of KDM5B/PLU1 
enhanced the invasive potential of cancer cells through repressing KAT5 and CD82 
expression,13 the involvement of KDM5B in EMT remained unknown. Here we identified a 
novel important role of KDM5B that contributed to EMT, another hallmark of cancer 
aggressiveness. Overexpression of KDM5B was shown to promote the EMT process of the 
cells by increasing the expression of ZEB1 and ZEB2 transcription factors through the 
regulation of microRNA-200 family expression. Moreover, we have observed 
KDM5B-induced EMT both in cancer cells, A549 and HT29, and benign epithelial cells, 
NMuMG, which might ensure the generality of novel function of KDM5B.  
      The members of the miR-200 family are important regulators of EMT. Deregulation of 
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miR-200 family expression occurred in multiple types of cancer cells and was linked to 
tumor progression.30, 31 It was proposed that the expression of miR-200 family was 
controlled by epigenetic mechanisms.33, 38 Increased EZH2 activity in cancer was shown to 
cause repression of numerous microRNAs including miR-200b and miR‑200c through 
H3K27me3 regulation at these loci.39 A recent paper also demonstrated that knockdown of 
JMJD3 H3K27 demethylase decreased the expression of miR‑200b and miR‑200c for 
up-regulation of EMT inducers such as ZEB1 and ZEB2,40 suggesting the importance of 
H3K27 methylation in the regulation of miR-200 family expression. Furthermore, a recent 
genome-wide profiling of histone methylation during EMT revealed strong correlations 
between the dynamic changes of histone methylations and gene expression.19 For genes 
with bivalent marks with H3K4me3 and H3K27me3, the level of transcription was shown 
to be dependent on the relative intensities of active H3K4me3 and repressive H3K27me3 
marks. This was closely correlated with our results of ChIP experiments: overexpression of 
KDM5B induced the decrease of H3K4me3 and the increase of H3K27me3 on the 
regulatory regions of the miR-200 family, resulting in decreased expression, but KDM5B 
knockdown caused the opposite changes of histone methylations for the increased 
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expression of the miR-200 family. 	   
    KDM5B has been found highly expressed in various types of tumors such as breast, 
prostate, bladder and lung cancers.	 23,	 24,	 26 Increased expression of KDM5B caused 
proliferation in breast cancer and depletion of KDM5B inhibited tumor growth in a mouse 
mammary tumor model.25 KDM5B can demethylate H3K4me3/me2 and was shown to 
regulate the expression of various cellular genes including BRCA1 tumor suppressor, E2F1 
and E2F2 genes.25,	 26 In this study, we identified miR-200 family genes as the novel target 
genes regulated by KDM5B. Overexpression of KDM5B led to the repression of miR-200 
family genes and KDM5B knockdown increased their expression. The recruitment of 
KDM5B and the changes of histone H3 methylation could be detected on the regulatory 
regions of miR-200 family genes like the cases of BRCA1 and HOXA5 genes that have been 
already reported as KDM5B-targets. Furthermore, introduction of miR-200 precursor was 
shown to inhibit EMT phenotype of the cells induced by KDM5B. These findings strongly 
suggested that miR-200 family was an important downstream mediator of KDM5B-induced 
EMT, although we could not rule out the possibility that other target genes regulated by 
KDM5B might be also involved in EMT. 
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     We have also detected that ectopic expression of KDM5B increased the cell invasion 
activity of A549 lung cancer cells and repressed the expression of other KDM5B target 
genes, KAT5 and CD82, that we previously described (13 and unpublished results). Since 
CD82 is involved in integrin-mediated cell migration, these results suggested that KDM5B 
might affect both EMT and integrin-mediated pathway leading to cell invasion in A549 
cells. However, in MCF10A immortalized breast epithelial cells, KDM5B overexpression 
enhanced cell invasion, but had no effect in CDH1 expression,13 suggesting that EMT might 
not be necessary for cell invasion activity of MCF10A cells. Therefore, epigenetic 
regulation by KDM5B might be differently involved in EMT or cell invasion process in 
different type of cell lines. Further studies using various cancer cell lines would be required 
to extend our understanding for KDM5B function in malignant progression.  
    By the knockdown experiments for KDM5B, we provided the evidence supporting the 
role of endogenous KDM5B in the transcriptional regulation of EMT-related genes. 
KDM5B knockdown increased CDH1 expression and decreased the expression of ZEB1 
and ZEB2 through up-regulation of the microRNA-200 family. Alteration of histone H3 
methylation on the regulatory regions of the microRNA clusters was suggested to be the 
-	 29	 -	 
underlying mechanism, although the recruitment of endogenous KDM5B on the regulatory 
regions was not be detected probably due to the low level of protein expression or low 
sensitivity of the available antibodies. We found that endogenous KDM5B was slightly but 
significantly induced by TGF-β treatment in A549 cells, but KDM5B knockdown could not 
counteract with TGF-β-induced EMT process. However, this result did not weaken the 
importance of endogenous KDM5B function in EMT process. Since TGF-β operated at the 
upstream of signaling pathway and activated various signaling molecules, transcription 
factors and epigenetic regulators in the cells for EMT induction, it was possible that 
KDM5B knockdown could not interrupt the profound effects caused by TGF-β. Further 
studies would be essential to delineate the precise role of endogenous KDM5B in the 
process of EMT.  
      In this paper, we have shown the important function of KDM5B histone demethylase in 
EMT. The regulation of the miR-200 family expression through histone H3 methylation 
was shown to be a novel mechanism for KDM5B action. These findings strongly suggest 
that deregulation of histone methyl-modifying enzymes and microRNA expression 
contributes to a critical step for malignant progression of cancer. Our study reveals a novel 
-	 30	 -	 
epigenetic mechanism regulating EMT and has important implications in devising novel 
targets for therapeutic interventions in the treatment of aggressive cancers. 
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Material and Methods 
Plasmids, cell culture and transfection 
  The construction of the retrovirus vectors expressing mouse KDM5B or its inactive 
mutant H499Y was described previously.13 To produce pantropic retroviruses for the 
infection of human cells, the retrovirus vectors were co-transfected into GP2-293 packaging 
cells (Takara) with pVSV-G plasmid (Takara) using FuGENE HD reagent (Roche). To 
produce ecotropic retroviruses for the infection of mouse cells, the retrovirus vectors were 
transfected into Plat-E packaging cells.11 Forty-eight hours after transfection, the 
supernatants were collected. The retroviral stock was added into the medium with 6µg/ml 
polybrene (Sigma) for infection. The infected cells were selected in the medium containing 
800µg/ml G418 (nacalai) for two to five days, and used for the experiments.  
   A549 human lung cancer cell line, HT29 human colon cancer cell line and NMuMG 
mouse mammary epithelial cell line were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% FBS, 2mM glutamine and penicillin/streptomycin (Sigma) at 
37 oC in 5% CO2. For EMT induction, the cells were treated with 1 to 5 ng/ml of 
Transforming Growth Factor-beta (TGF-β) (R&D Systems) for 24 to 48 hours.  
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   The construction of shRNA-expressing retrovirus vectors expressing KDM5B shRNA#1, 
#2 and control shRNA was described previously.13 To produce shRNA-expressing 
retroviruses, the retrovirus vectors were co-transfected into HEK293T cells with MISSION 
Lentiviral Packaging Mix (Sigma-Aldrich). The infected cells were selected in the medium 
containing 500 ng/ml puromycin (Nacalai). As described previously,13 the knockdown 
efficiencies of KDM5B shRNA #1 and #2 were 82% and 77% reduction compared to the 
control, respectively. We used these two effective shRNA-expressing retroviruses in this 
study and essentially obtained the same effects of both. Therefore we presented the data of 
KDM5B shRNA#1 as a representative result.  
  Transfections of miRNA precursors (Ambion) were carried out with Lipofectamine 
RNAiMAX (Invitrogen) by reverse transfection procedure. Cells were transfected with 
pre-miR-200a (#PM10991), pre-miR-200c (#PM11714) or negative control #1 
(#AM17110) miRNA at a final concentration of 10 nM, and further incubated for three 
days and used for the experiments. 
 
Patient samples  
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 For gene expression studies, 24 tumor specimens were obtained from lung adenocarcinoma 
patients with written informed consent at Kanazawa University Hospital in Japan. RNA 
was obtained from the OCT-Compound-embedded frozen tissues (Tissue-Tek). The 
association between mRNA expressions was analyzed by Pearson correlation coefficient, 
and the results were summarized by scatter plot. All tests were two-sided and p-values < 
0.05 were considered statistically significant. The experiment was approved by the Ethics 
Committee of Kanazawa University School of Medicine. 
 
Quantitative PCR 
   RNA preparation and quantitative RT-PCR analysis were performed as described 
previously.11 PCR data were normalized with respect to control human GAPDH, human 
DDX5 or mouse Actb expression.  The averages from at least three independent 
experiments are shown with the standard deviations. In the quantitative PCR experiments, 
Student’s t-tests were used to determine the statistical significance of differences between 
samples treated under different conditions. Differences were considered statistically 
significant when p < 0.05. Primers used for the quantitative PCR were described previously 
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13 and listed in Supplementary Table S1.  
  For microRNA quantification, TaqMan MicroRNA Assays (Applied Biosystems) for 
miR-200a (#000502), miR-200c (#002300) and miR-302a (#000529) were used according 
to the manufacture’s protocol. The relative miRNA levels were calculated using the 
formula 2-ΔΔCt. All data were normalized with respect to the expression of RNU6B 
(#001093) for human or snoRNA202 (#001232) for mouse. 
 
Immunoblotting.  
Cells were lysed in RIPA buffer as described previously.27 The lysates were separated on 
SuperSep Ace 10% running gel (Wako) and transferred to HybondTM-LFP membrane (GE 
Healthcare). Anti-E-cadherin (#610181, BD Transduction Lab), anti-ZEB1 (#3396, Cell 
Signaling), anti-ZEB2 (#61096, Active Motif) and anti-GAPDH (6C5, Millipore) 
antibodies were used.  
 
Chromatin immunoprecipitation (ChIP) assays 
  ChIP experiments were performed as previously described.13, 28 The cross-linked 
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chromatins were immunopreciptated with mouse antibody (anti-H3K27me3, 
anti-H3K4me3, anti-FLAG (M2, Sigma) and normal IgG), and the complexes were 
collected by Dynabeads M-280 sheep anti-mouse IgG (Invitrogen). The enrichment of the 
specific amplified region was analyzed by quantitative PCR and percentage enrichment of 
each histone modification over input chromatin DNA was shown. The averages from at 
least three experiments are presented with the standard deviations. 
 
Cell staining and immuno-fluorescence assay 
    To detect the morphological changes of the cells, A549 or NMuMG cells were fixed with 
4% paraformaldehyde in phosphate-buffered saline (PBS) and stained with 0.4 % crystal 
violet (Waldeck). To allow direct fluorescence of actin cytoskeleton, A549 cells were fixed, 
permeabilized with 0.2% Triton X-100 in PBS for 2 min, and subsequently stained with 
0.25 µM tetramethylrhodamine isothiocyanate (TRITC)-conjugated phalloidin (Sigma). For 
indirect immunofluorescence, the specimens were incubated with anti-E-cadherin antibody 
(BD Biosciences) and treated with Alexa546-conjugated anti-mouse IgG antibody 
(Invitrogen). Nuclei were visualized with 4’,6-diamidino-2-phenylindole (DAPI). 
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Figure legends   
Figure 1.   Overexpression of KDM5B caused morphological changes of A549 cells.  
(A) Cell morphological changes of A549 cells induced by KDM5B. A549 cells infected 
with the control retrovirus, the control retrovirus with TGF-β treatment, or the retrovirus 
expressing FLAG-tagged wild-type (WT) KDM5B or the H499Y mutant (Mut), were 
stained with crystal violet. (B) Immunofluorescence images of cells showing the 
localization of E-cadherin. The panels of A549 cells with the same arrangement with (A) 
were stained with anti-E-cadherin antibody and with DAPI. (C) Fluorescence images of 
cells showing reorganization of actin cytoskeleton. The cells were stained with 
TRITC-phalloidin (indicated as Actin) and with DAPI.  
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Figure 2.   KDM5B affected the expression of EMT-related genes.  
Quantitative RT-PCR analysis was performed to detect the expression of CDH1/E-cadherin 
(A), FN1/Fibronectin (B), CDH2/N-cadherin (C), SNAI1 (D), SNAI2 (E), ZEB1 (F) and 
ZEB2 (G) in A549 cells infected with the control retrovirus, the control retrovirus with 
TGF-β treatment, or the retrovirus expressing wild-type (WT) KDM5B or the mutant 
(Mut). PCR data were normalized with respect to control human GAPDH expression. The 
averages from at least three experiments are presented with the standard deviations (∗, P < 
0.001 comparing to control). (H) Western blotting was performed to detect the expression 
of E-cadherin, ZEB1 and ZEB2 proteins using the corresponding antibodies. As a control, 
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Figure 3.   Recruitment of KDM5B was not detected on the regulatory regions of 
CDH1/E-cadherin, ZEB1 and ZEB2 genes.  
Schematic of the regulatory regions of CDH1/E-cadherin (A), ZEB1 (C) and ZEB2 genes 
(E) is presented. The boxes shown on the scheme indicate the first and second exons and 
the dark area corresponds to the coding region. The arrow points to the transcription 
initiation site. The regions covered by the primer sets used for ChIP assays are shown as a. 
ChIP analyses of H3K4me3, H3K27me3 and FLAG-tagged KDM5B on the regulatory 
regions of CDH1/E-cadherin (B), ZEB1 (D) and ZEB2 genes (F) are shown. Cross-linked 
chromatins from A549 cells infected with the control retrovirus or the retrovirus expressing 
wild-type KDM5B were immunoprecipitated with the specific antibodies. The occupancies 
of methylated histones or KDM5B protein on the regions were analyzed by quantitative 
PCR and presented as the percentages of enrichment over input DNA. The averages from at 
least three experiments are presented with the standard deviations (∗, P < 0.001 comparing 
to control; **, P < 0.05 comparing to control).  
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Figure 4.   KDM5B decreased the expression of miR-200a and miR-200c by converting the 
histone H3 methylation on the regulatory regions of miR-200 gene clusters. 
Quantitative RT-PCR analysis was performed to detect the expression of miR-200a (A), 
and miR-200c (B) in A549 cells infected with the control retrovirus, the control retrovirus 
with TGF-β treatment, or the retrovirus expressing wild-type (WT) KDM5B or the mutant 
(Mut). PCR data were normalized with respect to control human RNU6B expression (∗, P < 
0.001 comparing to control). Schematic representation of the regulatory regions of 
miR-200b/200a/429 (C) and miR-200c/141 genes (E) is shown.  The regions covered by the 
primer sets used for ChIP assays are shown as a and b.  ChIP analyses of H3K4me3, 
H3K27me3 and FLAG-tagged KDM5B on the regulatory regions of miR-200b/200a/429 
(D) and miR-200c/141 genes (F) are shown (∗, P < 0.001 comparing to control; **, P < 
0.005 comparing to control). 
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Figure 5.   Altered expression of EMT-related gene induced by KDM5B was cancelled 
with the introduction of exogenous miR-200.   
Quantitative RT-PCR analysis was performed to detect the expression of CDH1/E-cadherin 
(A), CDH2/N-cadherin (B), ZEB1 (C) and ZEB2 (D) in A549 cells infected with the control 
retrovirus, the retrovirus expressing wild-type KDM5B, KDM5B with miR-200a precursor 
and KDM5B with miR-200c precursor (∗, P < 0.001 comparing to KDM5B WT).  
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Figure 6.    Knockdown of KDM5B affected the expression of EMT-related genes in A549 
cells.  
Quantitative RT-PCR analysis was performed to detect the expression of CDH1 (A), FN1 
(B), CDH2 (C), ZEB1 (D) and ZEB2 (E) in A549 cells expressing control shRNA or 
KDM5B shRNA (∗, P < 0.001 comparing to control; **, P < 0.005 comparing to control). 
(F) Western blotting was performed to detect the expression of E-cadherin, ZEB1 and 
ZEB2 proteins using the corresponding antibodies. Quantitative RT-PCR for miR-200a (G) 
and miR-200c (H) was performed (∗, P < 0.001 comparing to control; **, P < 0.005 
comparing to control). (I, J) ChIP analysis of H3K4me3 and H3K27me3 on the regulatory 
regions a of miR-200b/200a/429 (I) and miR-200c/141 genes (J) in A549 cells expressing 
control shRNA or KDM5B shRNA (∗, P < 0.001 comparing to control; **, P < 0.005 
comparing to control; ***, P < 0.01 comparing to control). 
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Figure 7.    Significant association between KDM5B and ZEB family expressions in human 
lung cancer samples.  
Quantitative RT-PCR analysis was performed to detect the expression of KDM5B, ZEB1 
and ZEB2 in human lung cancer tissues (N=24). PCR data were normalized with respect to 
control human DDX5 expression. Association of KDM5B and ZEB1 expression (A) or 
KDM5B and ZEB2 expression (B) was estimated using Pearson correlation coefficient. The 
associations were significantly positive with r=0.442 (P < 0.05) and with r=0.601 (P < 
0.005), respectively.  
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Table S1  Quantitative PCR primers used in this study 
 
Gene Primer sequence (5’ to 3’ ) 
 
CDH1/E-cadherin F: tgcccagaaaatgaaaaagg  
R: gtgtatgtggcaatgcgttc  
FN1/Fibronectin F: cagtgggagacctcgagaag  
R: tccctcggaacatcagaaac 
CDH2/N-cadherin F: acagtggccacctacaaagg   
R: ccgagatggggttgataatg 
SNAI1 F: accccaatcggaagcctaact  
R: agatgagcattggcagcga  
SNAI2 F: gcctccaaaaagccaaactaca  
R: gctgaggatctctggttgtggt 
ZEB1 F: ttcaaacccatagtggttgct  
R: tgggagataccaaaccaactg 
ZEB2 F: caagaggcgcaaacaagc  
R: ggttggcaataccgtcatcc 
DDX5 F: tatggttggagtggcacaga  
R: ccagcaccaaacaaataggc 
Mouse Cdh1/E-cadherin F: aggagaacggtggtcaaaga  
R: gctggctcaaatcaaagtcc 
Mouse Fn1/Fibronectin F: ggaatggacctgcaaacctat 
R: catcatccagccttggtagg 
Mouse Cdh2/N-cadherin F: cattatcaaccccatctcagg 
R: tgcatgtgctctcaagtgaa 
Mouse Snai1 F: cttgtgtctgcacgacctgt 
R: caggagaatggcttctcacc 
Mouse Snai2 F: ctcacctcgggagcatacagc 
R: tgaagtgtcagaggaaggcggg 
Mouse Zeb1 F: ttcaaacccatagtggttgct 
R: tgggagataccaaaccaactg 
Mouse Zeb2 F: atgagcttcctaccgcatatgg 
R: tgtagtcttgtgctccatccag 
Mouse Actb/beta-Actin F: gctgtattcccctccatcgtg  
R: cacggttggccttagggttcag 
CDH1 gene region g F: aactactgttggggctgggt 
R: ggtgctaactgataggggtg 
CDH1 gene region f F: gatgttaggaaagcaatggg 
R: gtaaatgctgtccagggct 
CDH1 gene region e F: gaaacagagaagcaattcagtg 
R: cagtagatcaggtgtccaggg 
CDH1 gene region d F: ggctagtgagtggctgactc 
R: acaacttccctgtctgactcc 
CDH1 gene region c F: agtgagccaagaacacacca 
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R: tgtgccagtctctgtgctaag 
CDH1 gene region b F: aaggcaggaggatcgcttc 
R: tgtagagagacaagtcggggc 
CDH1 gene region a F: ttctgatcccaggtcttagtg 
R: gttgctagggtctaggtgggtta 
CDH1 gene region h F: ggataagaaagtgaggtcgg 
R: gatgtctttattctccagtaccc 
CDH1 gene region i F: caaaccgaggctaagagagtg 
R: cagagatggtgcttaatggg 
CDH1 gene region j F: gctttgttccacttgactgtt 
R: gcctcttattgtgataccca 
ZEB1 gene region g F: ccattctgtggtaaactatgtaac 
R: gtgatgcagaacccacagtt 
ZEB1 gene region f F: gtatcccctaccgtttgattt 
R: atacagctaaagaataggggaa 
ZEB1 gene region e F: tctatgacctgattcggtag 
R: tatgtcaacacggtgtccttg 
ZEB1 gene region d F: acttctagcctctctttcaatcc 
R: agagaggctacctgacccg 
ZEB1 gene region c F: gaaagtagtgctctctgccc 
R: agaccaggtaagagacataacg 
ZEB1 gene region b F: gctgctgtgccaagggaaa 
R: aggcgactgtgcaaccacc 
ZEB1 gene region a F: gctttggttcctgcgttattt 
R: ttctcctaaacacgtatttcctcg 
ZEB1 gene region h F: cagcaaatggcaacttgtg 
R: aatgaaagcagcagacagga 
ZEB1 gene region i F: tggaatatgtctgaaggtagga 
R: accacacaaggtttgatgct 
ZEB1 gene region j F: gagggctcagtagtgaatagg 
R: ctccatgctacaatgtatctcg 
ZEB2 gene region e F: ttggagtaagttggatgcgac 
R: tggttttcaattccctggtg 
ZEB2 gene region d F: ttcctcaactttcacagccg 
R: ctgtgtgttcaagggcagaaa 
ZEB2 gene region c F: ctttacagccacccttccac 
R: ggtctgtaagcctccaatgg 
ZEB2 gene region b F: gtgttcttaaccaatgctctgct 
R: cctgtgctcagcatcctca 
ZEB2 gene region a F: cctttggcatcattatcctcat 
R: actttcgccccttggagttc 
ZEB2 gene region f F: aaacctacctgcgaagtcttgtt 
R: cgacactcttggcgaggttt 
ZEB2 gene region g F: tgcctgttactcctaagtctg 
R: ccaggaacagtgatgagcc 
ZEB2 gene region h F: ggagtttatcgaggcactgtc 
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R: gacagtgtccaaagaggctta 
ZEB2 gene region i F: ggaaaagtttggttcgggc 
R: cttatcaatgaagcagccgat 
ZEB2 gene region j F: gagcgagaagtttcctttcc 
R: tgacggaggataactgagttt 
miR-200b/a/429 gene region a F: tatgggagcccaggggaca 
R: ctcgccttacaaggagcagtg 
miR-200b/a/429 gene region b F: gctgtgggtctgtggggtct 
R: tttggagcaatgaagggacc 
miR-200c/141 gene region a F: agggctcaccaggaagtgt 
R: ttgggtcaggcagcttcag 
miR-200c/141 gene region b F: gaaggggttaaggcagtgg 
R: cctccgctcttcctcctt 
GAPDH gene region a F: tactagcggttttacgggcg 
R: gaggctgcgggctcaattt 
GAPDH gene region b F: atcgtgaccttccgtgcaga 
R: catctcctggctcctggcat 
BRCA1 gene region a F: aatcagaggatgggaggga 
R: ctttatggcaaactcaggtagaa 
BRCA1 gene region b F: agtagtcttgtaaggtcagtggc 
R: taacaaacactggggctgag 
HOXA5 gene region a F: tgtgtgcttgatttgtggct 
R: cgtaggagggaaccaagtacat 
HOXA5 gene region b F: tgtgtagtgtttctccaaggc 
R: aaatcgcaaactaatgacacg 
F: Forward,  R: Reverse  
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